{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:01:04Z","timestamp":1788818464786,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA210084"],"award-info":[{"award-number":["R35 CA210084"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007812","name":"University of Washington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007812","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015208","name":"Comprehensive Transplant Institute, University of Alabama at Birmingham","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015208","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016253","name":"Atara Biotherapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016253","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017577","name":"CTI Biopharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017577","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jtct.2022.07.015","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T02:25:41Z","timestamp":1658456741000},"page":"727-736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9216-2418","authenticated-orcid":false,"given":"Scott R.","family":"Goldsmith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Ghobadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Dipersio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayzar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6854-773X","authenticated-orcid":false,"given":"Tania","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.07.015_bib0001","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1016\/j.bbmt.2015.07.032","article-title":"Indications for autologous and allogeneic hematopoietic cell transplantation: guidelines from the American Society for Blood and Marrow Transplantation","volume":"21","author":"Majhail","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.015_bib0002","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.608916","article-title":"Hematopoeitic cell transplantation and CAR T-cell therapy: complements or competitors?","volume":"10","author":"Goldsmith","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2022.07.015_bib0003","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.015_bib0004","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","article-title":"Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed\/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy","volume":"25","author":"Jain","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.015_bib0005","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJMe2118899","article-title":"CAR T-cell therapy for large B-cell lymphoma\u2014who, when, and how?","volume":"386","author":"Roschewski","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0006","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/sj.bmt.1703772","article-title":"\u201cRelative\u201d chemotherapy sensitivity: the impact of number of salvage regimens prior to autologous stem cell transplant for relapsed and refractory aggressive non-Hodgkin's lymphoma","volume":"30","author":"Chen","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.015_bib0007","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1182\/bloodadvances.2020002346","article-title":"Navigating the narrow bridge to CAR T-cell therapy","volume":"4","author":"Yang","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.07.015_bib0008","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1182\/bloodadvances.2020001837","article-title":"Bridging therapy prior to axicabtagene ciloleucel for relapsed\/refractory large B-cell lymphoma","volume":"4","author":"Pinnix","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.07.015_bib0009","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2022.07.015_bib0010","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0011","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.015_bib0012","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2022.07.015_bib0013","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0014","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.bbmt.2016.12.003","article-title":"Ruxolitinib prevents cytokine release syndrome after CAR T-cell therapy without impairing the anti-tumor effect in a xenograft model","volume":"23","author":"Kenderian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.015_bib0015","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1182\/blood.2020004823","article-title":"Ruxolitinib for the treatment of steroid-refractory acute GVHD (REACH1): a multicenter, open-label phase 2 trial","volume":"135","author":"Jagasia","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0016","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0017","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.07.015_bib0018","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-139904","article-title":"The dual PI3K\u03b4\u03b3 inhibitor duvelisib potently inhibits IL-6 production and cytokine release syndrome (CRS) while maintaining CAR-T function in vitro and in vivo","volume":"136","author":"Amatya","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0019","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0020","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0021","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma","volume":"316","author":"Philip","year":"1987","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.07.015_bib0022","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/hon.2845","article-title":"Allogeneic stem cell transplant in non-Hodgkin lymphomas: still an indication?","volume":"39","author":"Dreger","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.07.015_bib0023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.07.015_bib0024","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0026","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.07.015_bib0027","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0028","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0029","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.07.015_bib0030","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1182\/blood-2021-147598","article-title":"Patient-reported outcomes in a phase 3, randomized, open-label study evaluating the efficacy of axicabtagene ciloleucel (Axi-Cel) versus standard of care therapy in patients with relapsed\/refractory large B-cell lymphoma (ZUMA-7)","volume":"138","author":"Elsawy","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0031","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1182\/blood.2021013289","article-title":"Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission","volume":"139","author":"Shadman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0032","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.bbmt.2019.12.771","article-title":"Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic transplantation?","volume":"26","author":"Dreger","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.015_bib0033","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1182\/bloodadvances.2020003036","article-title":"CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison","volume":"4","author":"Dreger","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.07.015_bib0034","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-019-0205-9","article-title":"Current status of autologous stem cell transplantation for multiple myeloma","volume":"9","author":"Al Hamed","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2022.07.015_bib0035","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0036","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.07.015_bib0037","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2020-134538","article-title":"Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial","volume":"136","author":"Perrot","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0038","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1056\/NEJMe1700453","article-title":"Transplantation for myeloma\u2014now or later?","volume":"376","author":"Schiffer","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0039","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2022.07.015_bib0040","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3390\/jcm9072180","article-title":"Allogeneic transplantation in multiple myeloma\u2014does it still have a place?","volume":"9","author":"Gahrton","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0041","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(11)70243-1","article-title":"Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial","volume":"12","author":"Krishnan","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.07.015_bib0042","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.bbmt.2019.11.018","article-title":"Tandem autologous-autologous versus autologous-allogeneic hematopoietic stem cell transplant for patients with multiple myeloma: long-term follow-up results from the Blood and Marrow Transplant Clinical Trials Network 0102 trial","volume":"26","author":"Giralt","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.015_bib0043","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1038\/s41409-020-0887-4","article-title":"Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation","volume":"55","author":"Costa","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.015_bib0044","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.bbmt.2017.07.003","article-title":"Allogeneic blood or marrow transplantation with post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis in multiple myeloma","volume":"23","author":"Ghosh","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.015_bib0045","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2017-06-793869","article-title":"Chimeric antigen receptor T-cell therapies for multiple myeloma","volume":"130","author":"Mikkilineni","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0046","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.07.015_bib0047","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-cell therapy bb2121 inrelapsed or refractory multiple myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0048","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.jtct.2022.07.015_bib0049","doi-asserted-by":"crossref","first-page":"8013","DOI":"10.1200\/JCO.2021.39.15_suppl.8013","article-title":"CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy","volume":"39","author":"Agha","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.07.015_bib0050","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2021-146074","article-title":"CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell therapy, in patients with multiple myeloma and early relapse after initial therapy","volume":"138","author":"van de Donk","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0051","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2018-10-881961","article-title":"A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403","volume":"133","author":"Stock","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0052","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2012-07-445098","volume":"121","author":"Gupta","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0053","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2015.62.4544","article-title":"Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group Study AALL0232","volume":"34","author":"Larsen","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.07.015_bib0054","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0055","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1056\/NEJMoa1509277","article-title":"Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia","volume":"375","author":"Kantarjian","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2021.101256","article-title":"CAR T in adult ALL: when and for whom?","volume":"34","author":"Connor","year":"2021","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.jtct.2022.07.015_bib0057","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2021000225","article-title":"Relapsed ALL: CAR T vs transplant vs novel therapies","volume":"2021","author":"Frey","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2022.07.015_bib0058","doi-asserted-by":"crossref","first-page":"S126","DOI":"10.1016\/j.bbmt.2018.12.410","article-title":"Tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia: updated analysis of the ELIANA clinical trial","volume":"25","author":"Grupp","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.015_bib0059","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0060","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"issue":"suppl 2","key":"10.1016\/j.jtct.2022.07.015_bib0061","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41409-019-0604-3","article-title":"The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia","volume":"54","author":"Jacoby","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.07.015_bib0062","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/ajh.25582","article-title":"Anti-CD19 chimeric antigen receptor-modified T-cell therapy bridging to allogeneic hematopoietic stem cell transplantation for relapsed\/refractory B-cell acute lymphoblastic leukemia: an open-label pragmatic clinical trial","volume":"94","author":"Jiang","year":"2019","journal-title":"Am J Hematol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2022.07.015_bib0063","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood-2018-99-112599","article-title":"Updated analysis of the efficacy and safety of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory (r\/r) acute lymphoblastic leukemia","volume":"132","author":"Grupp","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0064","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0065","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0066","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.07.015_bib0067","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1200\/JCO.20.02262","article-title":"Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.07.015_bib0083","doi-asserted-by":"crossref","unstructured":"Blood Cancer Discov. 2022 Jan;3(1):66\u201381. https:\/\/doi.org\/10.1158\/2643-3230.BCD-21-0095","DOI":"10.1158\/2643-3230.BCD-21-0095"},{"key":"10.1016\/j.jtct.2022.07.015_bib0068","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1056\/NEJM197504172921605","article-title":"Bone-marrow transplantation (first of two parts)","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0069","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJM197504242921706","article-title":"Bone-marrow transplantation (second of two parts)","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0268-960X(96)90004-1","article-title":"The history of bone-marrow transplantation","volume":"10","author":"Perry","year":"1996","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtct.2022.07.015_bib0071","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0140-6736(83)91793-2","article-title":"Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia","volume":"1","author":"Powles","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.jtct.2022.07.015_bib0072","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1148\/58.6.863","article-title":"Modification of acute irradiation injury in mice and guinea pigs by bone marrow injections","volume":"58","author":"Lorenz","year":"1952","journal-title":"Radiology"},{"key":"10.1016\/j.jtct.2022.07.015_bib0073","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1172\/JCI80010","article-title":"CAR therapy: the CD19 paradigm","volume":"125","author":"Sadelain","year":"2015","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2022.07.015_bib0074","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0075","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced T lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtct.2022.07.015_bib0076","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1182\/blood.V96.5.1999","article-title":"Chimeric Fv-zeta or Fv-epsilon receptors are not sufficient to induce activation or cytokine production in peripheral T cells","volume":"96","author":"Brocker","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.07.015_bib0077","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1084\/jem.188.4.619","article-title":"Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes","volume":"188","author":"Krause","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.jtct.2022.07.015_bib0078","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2022.07.015_bib0079","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf\u2019 allogeneic CAR T cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtct.2022.07.015_bib0080","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ymthe.2017.02.005","article-title":"Integration of a CD19 CAR into the TCR alpha chain locus streamlines production of allogeneic gene-edited CAR T cells","volume":"25","author":"MacLeod","year":"2017","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtct.2022.07.015_bib0081","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2018.05.013","article-title":"Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia","volume":"173","author":"Kim","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.jtct.2022.07.015_bib0082","unstructured":"Liu F, Zhang H, Sun L, et al. First-in-human CLL1-CD33 compound CAR (CCAR) T cell therapy in relapsed and refractory acute myeloid leukemia. Presented at the 25th European Hematology Association Congress [virtual], June 11-21, 2020:S149."}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722014774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722014774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:05:31Z","timestamp":1763003131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722014774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":83,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2666636722014774"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.07.015","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor T Cell Therapy versus Hematopoietic Stem Cell Transplantation: An Evolving Perspective","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}